Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

REFILE-Nestle enters agreement to develop ulcerative colitis therapy

Published 2015-09-16, 08:53 a/m
© Reuters.  REFILE-Nestle enters agreement to develop ulcerative colitis therapy
NESN
-

(Refiles to remove extraneous Reuters Instrument Code)
ZURICH, Sept 16 (Reuters) - Nestle NESN.VX is working with
Lipid Therapeutics to develop and commercialise a new
therapeutic treatment for mild-to-moderate ulcerative colitis,
which can causes ulcers, bleeding and pain due to inflammation
of the colon, the company said on Wednesday.
Nestle Health Science intends to develop an add-on therapy
to an existing one that is commonly used but with which 40
percent of patients continue to experience flare-ups, the
company said.
The LT-02 compound under development by Nestle can help to
heal ulcers and restore lining of the colon wall, reducing
chances of the condition returing. The agreement is part of
Nestle Health Science's strategy to develop its product
portfolio for gastrointestinal diseases, it said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.